

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

SUPPLEMENTAL ANNOUNCEMENT

MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF THE ENTIRE ISSUED SHARE CAPITAL IN PHC MEDICAL DIAGNOSTIC CENTRE LIMITED AND PREMIER MEDICARE SERVICES LIMITED

Reference is made to the announcement of China Biotech Services Holdings Limited dated 18 May 2026 in relation to the disposal of the Sale Shares of the Target Companies (the “**Announcement**”). Unless the context otherwise requires, terms defined in the Announcement shall have the same meaning when used in this announcement.

SUPPLEMENTAL INFORMATION IN RELATION TO REASONS FOR AND BENEFITS OF THE DISPOSAL

As at 31 March 2026, the unaudited net liabilities of the Target Companies amounted to approximately HK\$29,013,000, which represented the total unaudited net liabilities of PHC and PMS. Such net liabilities mainly arose from the funding support provided by the Company and its subsidiaries to the Target Company in the form of intercompany advances. The Hong Kong laboratory testing business operated by the Target Company has been facing intense market competition and persistently high operating costs, resulting in reduced cash flow and continuous losses. As a result, the Target Company has been unable to generate sufficient cash flow from its own operations to repay such intercompany advances to the Company and its subsidiaries.

The financial position of the Group’s other businesses remains overall stable with sufficient liquidity. The Disposal represents a commercial and strategic decision made by the Board after prudent evaluation, with the objective of concentrating the Group’s resources and efforts on developing its high-growth-potential cancer treatment business segment. This includes, but is not limited to, the operation of Pengbo (Hainan) Boron

Neutron Hospital (which is currently in the trial operation stage and has already completed multiple treatment cases), as well as the provision of a comprehensive one-stop solution covering equipment sales, installation and commissioning, hospital design, turnkey construction works and maintenance services. Such solution leverages the Group's role as the exclusive agent in the Greater China region for NeuCure®, the world's first approved boron neutron capture therapy equipment, and its consumables.

In addition, the Group has entered into a memorandum of understanding with Stella Pharma Corporation, pursuant to which the parties will jointly advance the regulatory approval process of Steboronine®, the world's first boron neutron capture therapy drug, by the National Medical Products Administration, with a view to supporting the launch of the drug in China and localising its production. According to the memorandum of understanding, the said company intends to grant the Group exclusive rights to manufacture and sell such licensed products in China, and the Group expects to be able to significantly expand the scale of its production and sales. This initiative will accelerate the Group's upstream positioning in the boron neutron capture therapy industry and strengthen its future competitiveness. The Group will continue to focus on the development of new technologies and products, thereby enhancing the Group's overall operational efficiency and long-term shareholder value.

Save as supplemented or clarified above, all other information in the Announcement remains unchanged.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 2 June 2026

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Liu Xiaolin (Chairman), Dr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.